Pharmaceutical technology has introduced a promising pathway in the future of medicine in particular nanotechnological innovations
have provided the opportunity to design and develop efficient drug delivery systems able to target and treat several diseases,
including those mediated by inflammation. The engineering of drug delivery systems can be used to target tissues involved in the pathology
under treatment, to avoid early drug biological environmental degradation and to modulate drug pharmacokinetics. Glucocorticoids
and non-steroidal anti-inflammatory drugs are the most commonly prescribed drug categories worldwide for the treatment of disorders
associated with inflammation.
Although glucocorticoids can be highly effective in treating inflammation, their systemic application is limited due to the high incidence
of serious adverse effects, mainly in long-term treatment. Non-steroidal anti-inflammatory drugs are a heterogeneous group of compounds
and most of them have unfavorable pharmacokinetics and pharmacodynamics, leading to adverse effects, such as gastrointestinal
disorders. Therefore, the need for drug delivery systems for long term administration of anti-inflammatory drugs with a well-controlled
release profile is evident. The aim of this review is to assess innovative colloidal drugs carriers, in particular liposomes and nanoparticles,
with special focus on site-specific delivery for particularly problematic tissues such as the gastrointestinal tract, joints and eyes.